3/11
08:15 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its price target lowered by analysts at HC Wainwright from $64.00 to $55.00. They now have a "buy" rating on the stock.
High
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its price target lowered by analysts at HC Wainwright from $64.00 to $55.00. They now have a "buy" rating on the stock.
3/10
10:37 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
3/10
08:07 am
urgn
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 [Yahoo! Finance]
Medium
Report
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 [Yahoo! Finance]
3/10
08:00 am
urgn
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
Medium
Report
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
3/7
08:00 am
urgn
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/27
08:00 am
urgn
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
Low
Report
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
2/25
08:00 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.
High
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.
2/24
04:00 pm
urgn
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
Low
Report
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
2/21
11:04 am
urgn
UroGen acquires IconOVir's oncolytic virus assets [Yahoo! Finance]
Medium
Report
UroGen acquires IconOVir's oncolytic virus assets [Yahoo! Finance]
2/20
08:16 am
urgn
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations [Yahoo! Finance]
Low
Report
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations [Yahoo! Finance]
2/20
08:00 am
urgn
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
Low
Report
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
2/19
08:01 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $31.00 price target on the stock.
Low
Report
UroGen Pharma Ltd. (NASDAQ: URGN) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $31.00 price target on the stock.
2/18
08:00 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
2/14
03:02 pm
urgn
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 [Yahoo! Finance]
Low
Report
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 [Yahoo! Finance]
2/14
02:30 pm
urgn
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
Low
Report
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
2/12
10:36 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Low
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
2/12
08:31 am
urgn
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology [Yahoo! Finance]
Low
Report
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology [Yahoo! Finance]
2/12
08:00 am
urgn
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
Medium
Report
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
1/30
08:15 am
urgn
UroGen Pharma to Present at Upcoming Investor Conferences [Yahoo! Finance]
High
Report
UroGen Pharma to Present at Upcoming Investor Conferences [Yahoo! Finance]
1/30
08:00 am
urgn
UroGen Pharma to Present at Upcoming Investor Conferences
High
Report
UroGen Pharma to Present at Upcoming Investor Conferences
1/23
08:02 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
1/22
08:00 am
urgn
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
Low
Report
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
1/15
11:22 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
1/15
08:38 am
urgn
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 [Yahoo! Fi
Low
Report
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 [Yahoo! Fi
1/15
08:00 am
urgn
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
Medium
Report
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025